IL2 and cancer: Indeed, in patients with a persistent or heavy disease burden, T cells are often identifiable with tetramers, but not through stimulation assays that measure interferon-gamma (IFN-γ) or interleukin-2 (IL-2) secretion as a means of detecting the presence of cancer-specific T cells (24).